Compare Nerdwallet Inc (NRDS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nerdwallet Inc trades at $9.74 (market cap $625.17M), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 16.2× Nerdwallet Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NRDS | XBI | |
|---|---|---|
Market Cap | $625.17M | $10.11B |
Volume | 1,321,316 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $15.93 | $169.55 |
52-Week Low | $7.58 | $104.99 |
Typical Hold Time | 45 Days | 38 Days |
Enterprise Value | $539.47M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.74, up 7.21% today, showing strong momentum despite a recent Q2 2026 earnings miss. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Fundamentally, the company demonstrates robust revenue growth from $539M in 2022 to $837M in 2025, with improving profitability margins. Recent news highlights the company's Financial Resilience Index publications and Wall Street's positive outlook.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key opportunities include continued revenue growth and margin expansion, while risks involve organic search pressure in core products and macroeconomic sensitivity. The stock presents a compelling value proposition with attractive valuation multiples.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
